NEW YORK (GenomeWeb News) – Maverix Biomics said this week that it has extended an existing co-marketing agreement with Qiagen by integrating a second set of software products to support customers analyzing data from RNA-sequencing studies.

The partners have combined Qiagen's Ingenuity Pathway Analysis software with the Maverix Analytic platform to simplify the analysis and interpretation of RNA-seq data as well as speed up research, Maverix said. Last November, the companies integrated Qiagen Ingenuity iReport with the Maverix platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.